Results from the world’s largest study investigating the ‘naturalistic’ use of psilocybin outside of research settings have shown lasting therapeutic benefits.
The European Medicines Agency (EMA) has updated its general guidelines on the development of medicinal products for Major Depressive Disorder (MDD) to include a section on...
California could decriminalise naturally occurring psychedelics and create a framework for their therapeutic use under a new bill.
MAPS PBC has published anticipated results from its Phase 3b study that could bring MDMA-assisted therapy closer to Food and Drug Administration (FDA) approval by 2024...
Ketamine has been an FDA-approved medical anaesthetic since 1970, and in the early 2000s a ground-breaking discovery was made about the antidepressant effects of ketamine.
A new research review has explored the use of psilocybin for the treatment of resistant depression.
In a new policy briefing for the European Medicines Agency (EMA), Psychedelic Access and Research European Alliance (PAREA) has called for an advisory body on psychedelics...
Findings from a landmark survey have revealed that people with experience using psychedelics exhibited elevated psychological well-being during the COVID-19 pandemic.
A new survey study carried out by The Beckley Foundation and Maastricht University has found that classical psychedelics such as psilocybin and LSD could have painkilling...
Jazz Pharmaceuticals, a leading global biopharmaceutical company, recorded an astonishing $1.8 billion in revenue this year from the sales of Gamma Hydroxybutyrate (GHB).
Johns Hopkins University School of Medicine (JHU) and Clearmind Medicine will be collaborating on research to investigate the use of a novel psychoactive molecule to treat...
Awakn Life Sciences has submitted a clinical trial application to investigate the use of AWKN-P001 – a novel combined therapeutic of an N-methyl-D-aspartate receptor-modulating drug (ketamine)...